SomnoMed Strengthens Leadership with New Director Appointment

Somnomed Limited ( (AU:SOM) ) just unveiled an update.

SomnoMed Limited has announced the appointment of Andrew Price as a non-executive director, effective January 17, 2025. As part of his engagement, Price will have the conditional right to be issued 300,000 options, pending shareholder approval. These options, with an exercise price of $0.69, will vest on the first anniversary of their grant date and expire four years from the commencement date. This appointment and the associated equity options are likely to impact the company’s governance and strategic direction as SomnoMed continues to strengthen its board with experienced leadership.

More about Somnomed Limited

SomnoMed Limited operates in the medical device industry, focusing on developing and providing oral appliances for the treatment of sleep-related disorders, such as obstructive sleep apnea. The company is known for its innovative solutions that offer an alternative to traditional CPAP machines, catering to a global market.

YTD Price Performance: 63.12%

Average Trading Volume: 4,787

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $63.55M

Learn more about SOM stock on TipRanks’ Stock Analysis page.